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Summary Iron deficiency and iron deficiency-asso-
ciated anemia are common complications in cancer 
patients. Most iron deficient cancer patients present with 
functional iron deficiency (FID), a status with adequate 
storage iron, but insufficient iron supply for erythroblasts 
and other iron dependent tissues. FID is the consequence 
of the cancer-associated cytokine release, while in abso-
lute iron deficiency iron stores are depleted resulting in 
similar but often more severe symptoms of insufficient 
iron supply. Here we present a short review on the epide-
miology, pathophysiology, diagnosis, clinical symptoms, 
and treatment of iron deficiency in cancer patients. Spe-
cial emphasis is given to intravenous iron supplemen-
tation and on the benefits and limitations of different 
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formulations. Based on these considerations and recom-
mendations from current international guidelines we 
developed recommendations for clinical practice and 
classified the level of evidence and grade of recommen-
dation according to the principles of evidence-based 
medicine.
Keywords Iron deficiency  · Functional and absolute 
iron deficiency · Tumor anemia · Iron supplementation · 
Recommendations for clinical practice
Introduction
Iron (Fe), an important trace element, plays a vital role 
in oxygen metabolism, oxygen uptake, and electron 
transport in mitochondria, energy metabolism, muscle 
function, and hematopoiesis. Iron, therefore, is essential 
for physical functioning and wellbeing, but free biva-
lent iron is quickly oxidized to its trivalent iron, which 
when available in its free form can induce the formation 
of free oxygen radicals which may result in tissue dam-
age [1]. Therefore, iron metabolism is tightly controlled 
to ensure that free iron levels are kept as low as possible, 
and to guarantee adequate iron absorption, transport, 
and storage.
In patients with chronic diseases or cancer, iron regu-
lation and homeostasis often are distorted [2]. This may 
result in insufficient iron supply to erythroblasts with 
clinical sequelae of iron deficiency such as weakness, 
fatigue, and impaired physical fitness and wellbeing as 
well as anemia. Treatment of iron deficiency in non-can-
cer patients has been shown to reverse these symptoms 
[3], and emerging data in cancer patients indicate a ben-
eficial effect of this approach [4].
Here, we briefly summarize the pathophysiology of 
iron metabolism with particular emphasis on cancer and 
review the available evidence for iron supplementation 
in patients with functional iron deficiency. Furthermore, 
we provide suggestions for clinical practice and respond 
to a series of clinically relevant questions. The issues pre-
sented in this report have been discussed during a per-
sonal meeting between the authors and thereafter during 
the preparation of this article after reviewing and assess-
ing the available scientific evidence. Literature research 
was conducted by searching PubMed Home/Medline, 
Cochrane Library, and the recommendations of ASCO, 
NCCN, ESMO, and EORTC between 1990 and March 2015 
for relevant key words. Furthermore, relevant abstracts 
from ASCO, ESMO, EHA, and MASCC meetings between 
2003 and March 2015 were used. After preparing a first 
version of this manuscript, the text was circulated and 
reviewed and modified by the authors in three rounds. 
Finally, a consensual wording was agreed for all state-
ments and questions.
Epidemiology
About 25 % of the world’s population is anemic, half 
because of iron deficiency. Individuals from develop-
ing countries are especially affected by this problem. 
Data from the USA show a prevalence of less than 1 % 
of iron deficiency and iron deficiency anemia in men 
under the age of 50. In men over 50 years of age, iron 
deficiency is noted in 2–4 % and iron deficiency anemia 
in 1–2 %. In premenopausal women, the prevalence of 
these complications is higher because of blood loss dur-
ing menstruation. Iron deficiency is found in 9–11 % of 
women between the age of 12 and 49 years and in 5–7 % 
of women above this age. The corresponding prevalence 
for iron deficiency anemia is 2–5 % in younger and 2 % in 
older female populations [5]. For Austria, precise epide-
miological data are not available.
The prevalence of anemia in patients with cancer is 
remarkably high. In the “European Cancer Anaemia 
Survey”(ECAS) 39 % of cancer patients were anemic at 
baseline when they were included in the survey. In those 
receiving chemotherapy incidence of anemia was noted 
in 67 % of patients at some point during a 6 month sur-
veillance phase (anemia was defined as hemoglobin 
(Hb) < 12 g/dl) [6]. Similar data have subsequently been 
obtained in a survey conducted in Austria [7]. Ane-
mia was correlated with low performance status [2], and 
many patients did not receive anemia therapy.
Presently, only limited data on iron deficiency in can-
cer patients are available [4, 8–11]. Expectedly, functional 
iron deficiency (FID) is much more prevalent than abso-
lute iron deficiency. Epidemiological studies on iron defi-
ciency reported prevalence rates for FID varying between 
29–46 %, and for iron deficiency-associated anemia 
between 7–42 % [2, 4, 9–11]. A recent study in patients with 
different cancer types revealed a very high prevalence of 
iron deficiency (functional and absolute) in patients with 
pancreatic cancer (63 %), followed by colorectal (52 %), 
and lung cancer (51 %) [2]. Most patients with absolute 
iron deficiency present with anemia [8] and anemia is 
associated with higher mortality in cancer patients [12], 
although a causal relationship between anemia and mor-
tality has not been established. Likewise, solid evidence 
supporting the claim that correction of anemia would 
improve prognosis is not available.
Several studies confirm a significant correlation 
between Hb levels and physical fitness and quality of life 
in cancer patients [6, 13]. In the aforementioned ECAS 
study, the group of patients with the lowest WHO perfor-
mance scores also had the lowest Hb levels [6]. In fact, in 
cancer patients a close correlation between the relevant 
range of hemoglobin levels (8–14 g/dl) and quality of life 
was reported.
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bound to transferrin and be further transported through 
the blood (Figure 2).
High hepcidin levels inhibit enteral iron resorption 
and release of iron from the RES, whereas low hepcidin 
levels create the opposite effects. Hepcidin production 
is stimulated by high iron plasma levels and inflamma-
tory processes, whereas low iron plasma levels, hypoxia, 
and increased erythropoiesis inhibit the expression of 
hepcidin [17]. The regulation of hepcidin transcription is 
heavily influenced by the “bone morphogenetic protein” 
receptor (BMP) which is activated through binding BMP 
and membrane-bound hemojuvelin (HJV) and then 
phosphorylates Smad4. Smad4, and RSmad form het-
erodimers which are translocated into the nucleus where 
they activate the transcription of the hepcidin-encoding 
HAMP-gene. Binding of soluble HJV to BMP obviates the 
formation of membrane-bound BMP-HJV complexes 
and thus the activation of the BMP receptor. Inflam-
matory proteins like IL-6 activate Stat3 which can also 
active the HAMP promotor and thus increase the tran-
scription of hepcidin [17]. Recently, erythroferrone has 
been described as probably the most important hepcidin 
regulator. Erythroferrone is produced by erythroblasts 
in response to erythropoietin. It suppresses hepcidin 
expression which in turn facilitates release of intracellu-
lar iron and enteral iron absorption [18].
Absolute and functional iron deficiency in cancer 
patients
Anemia is common in cancer patients [2]. From a prac-
tical viewpoint, two forms of iron deficiency need to be 
differentiated: absolute iron deficiency (AID) and func-
tional iron deficiency (FID). AID is defined by a TSAT 
< 20 % and a serum ferritin level < 30 ng/ml in otherwise 
normal individuals, while in cancer patients a higher cut 
off level of ferritin levels should be applied (< 100 ng/ml). 
FID is defined by a TSAT < 20 % and serum ferritin levels 
of > 30 ng/ml in normal individuals and of > 100 ng/ml in 
cancer patients.
In addition, there are hereditary disorders based on 
molecular defects of enzymes involved in iron transport, 
iron recycling, or iron utilization, which all can also lead 
to iron deficiency but which are not further elaborated 
on in this context (see Table 1).
AID is characterized by both depleted iron stores 
and insufficient iron supply, while in FID iron stores 
are loaded, but the deposited iron is unavailable for the 
erythroblast and for other iron-dependent processes 
like oxygen transport. This reduction in disposable 
iron (functional iron deficiency) is mainly mediated by 
increased hepcidin serum levels, which suppresses the 
release of adequate quantities of iron into the circulation 
and which inhibits enteral iron absorption (see Sect. 2) 
[19, 20].
FID is one of the leading causes for the so-called ane-
mia of chronic disease (ACD). The inadequate iron sup-
ply is due the above cited upregulation of hepcidin by 
Physiology and pathophysiology of iron 
metabolism
Iron is an essential cofactor for various enzyme systems 
which can be classified into heme and non-heme pro-
teins. About two third of the body’s total iron content of 
4–5 g is bound to heme-proteins, mainly hemoglobin and 
myoglobin. In both proteins iron is the central atom of 
heme, a porphyrin structure bound to the protein part of 
the molecules.
Ferrous (bivalent) iron of red cells circulating through 
pulmonary capillaries binds oxygen reversibly. Red 
cells deliver the oxygen to peripheral organs and tissues 
where oxygen is deployed and carbon dioxide is taken up 
in return. Hemoglobin serves as an intermediate oxygen 
storage in muscle cells and provides an oxygen reserve 
for short-term muscle activity [14]. Other additional 
iron-dependent functions pertain to oxygen metabo-
lism (mediated by oxydases, peroxydases, catalases, and 
others) and to mitochondrial electron transfer (cyto-
chromes). Iron-dependent non-heme proteins include 
enzymes of mitochondrial energy metabolism (such as 
mitochondrial aconitase or Fe-S complexes as part of the 
electron transfer chain), and enzymes of DNA synthesis 
(such as ribonucleotidereductase). In addition, iron-
containing proteins are also involved in the synthesis of 
collagen, tyrosine, and catecholamines [1–15].
Plasma iron levels are regulated by the glycoprotein 
transferrin which has two high affinity binding sites for 
trivalent iron. Transferrin, as the main iron transport 
protein, supplies iron to iron-dependent systems. The 
uptake of iron into cells is affected by the transferrin 
receptor (TfR1). By binding to transferrin, iron becomes 
soluble in plasma, and the synthesis of free oxygen radi-
cals by free trivalent iron is tightly limited. Normally, the 
iron-saturation of transferrin (TSAT) lies around 30 %; a 
TSAT below 20 % points to iron deficiency, a TSAT over 
45 % to iron overload. Above a TSAT of 60 %, free, non-
transferrin-bound iron is released into plasma and dam-
age of parenchymal cells can occur [16].
Iron finds its way into circulation via two paths (Fig-
ure 1): duodenal enterocytes absorb 1–2 mg of iron per 
day from nutrition, and macrophages release 20–25  mg 
iron per day from internalized senescent red cells. Hepa-
tocytes also play an important role in iron metabolism: 
They store large amounts of iron via ferritin, and they 
synthesize and secrete the regulatory protein hepcidin 
[16]. Hepcidin regulates  enteral iron uptake and the 
release of iron from the reticuloendothelial system (RES) 
by binding to the only cellular iron exporter, ferroportin, 
and degrading it [17].
Ferroportin is a membrane-bound transport protein, 
synthesized in liver, spleen, kidneys, heart, gut, and 
placenta. It is localized in the basolateral membrane of 
endothelial cells and there affects the efflux of iron into 
the blood. Ferroportin can only bind and transport fer-
rous (bivalent) iron. After passing the cell membrane and 
being oxidized to trivalent Fe by the plasma protein ceru-
loplasmin or the membrane protein hephestin, Fe can be 
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acute and/or chronic bleeding, hemolysis, vitamin B12 
and folic acid deficiency [20], renal failure, metastatic 
infiltration of bone marrow, and therapy-related factors 
like myelosuppression or hemolytic anemia caused by 
chemo- and/or radiotherapy.
Diagnosis of iron deficiency
Serum ferritin levels correlate with body iron content 
in individuals without inflammation or cancer. The 
amount of biologically available iron is reflected by vari-
ous parameters such as by transferrin saturation (TSAT), 
percentage of hypochromic erythrocytes (% HYPO), Hb-
content of reticulocytes (CHr), soluble transferrin recep-
tor (sTfR), and sTfR/ferritin index [22]. Ferritin is an acute 
phase protein, and usually is increased in inflammatory 
states or in conditions with damaged hepatocytes; this 
is why in these situations ferritin levels do not correlate 
with the storage iron, a fact which is especially true for 
cancer patients [23]. Therefore, presence of inflamma-
tion should be assessed by determination of C-reactive 
protein (CRP) levels. In specific cases cholinesterase, 
albumin, or INR (International Normalized Ratio) should 
be determined as well for gross exclusion of relevant liver 
function impairment.
Further sources of ferritin production are cancer cells 
which can produce ferritin themselves making them 
partly independent of external iron supply. This can 
result in marked increase in serum ferritin levels and in 
certain cancers ferritin has been shown to closely corre-
late with tumor stage. Besides its role as indirect tumor 
marker, ferritin seems to enhance tumor proliferation by 
stimulating angiogenesis and by suppressing the host’s 
immune system [24].
The serum levels of the soluble transferrin receptor 
(sTfR) are strongly increased in patients with AID, but 
reduced in those with ACD and chemotherapy-induced 
anemia, making this parameter unsuitable for the assess-
ment of iron homeostasis [25]. As mentioned before, 
serum ferritin level < 100  ng/ml in combination with a 
TSAT < 20 % indicate absolute iron deficiency (AID) in 
cancer patients [23]. The cut off level of serum ferritin for 
absolute iron deficiency in cancer has been set higher 
than the one for individuals without cancer (< 30 ng/ml), 
because of the non-iron specific increase in ferritin levels 
by subclinical or overt inflammatory processes.
A TSAT < 20 % points to an insufficient availability 
of iron for iron-dependent processes like erythropoi-
esis and oxygen transport. In a previous study on the 
correlation between TSAT and bone marrow iron con-
tent in patients with lymphoproliferative diseases, nor-
mal iron stores were found in 39 % of patients with low 
TSAT (< 20 %) indicating the presence of FID in spite of 
adequate storage iron [4, 11, 26]. These patients were 
then treated with erythropoietin and randomized into a 
group that received intravenous iron supplementation 
and a control group. Patients treated with intravenous 
iron showed a significant increase in TSAT, whereas TSAT 
pro-inflammatory cytokines such as IL-6, IL-1, TNF-α, 
and interferon-γ, and anti-inflammatory cytokines such 
as IL-10 [19, 21].
A reduced erythropoietic activity also might contrib-
ute to increased hepcidin levels, by a diminished pro-
duction of erythroferrone. Hepcidin binds to ferroportin 
leading to internalization and intracellular degradation 
of the latter. Hepcidin, is made up of 20 amino acids, and 
is the master regulator in the development of FID in the 
context of chronic disease [19] including anemia of can-
cer, chronic inflammatory bowel disease, rheumatoid 
arthritis, infections, and other diseases with increased 
production of inflammatory cytokines [20].
Importantly, several other mechanisms can cause 
or aggravate anemia in cancer patients. These include 
Table 1 Pathophysiology of iron deficiency. (Source: modi-
fied from [17])
Absolute iron deficiency Growth/Development
In women:
 Pregnancy/breast feeding
 Menstrual blood losses
Chronic blood loss:
 Blood donation
 Nonsteroidal anti-inflammatory drugs 
(NSAIDs)
 Gastrointestinal neoplasms, Gastrointesti-




 Helicobacter pylori infection
 Autoimmune atrophic gastritis
 Gastrectomy
Functional iron deficiency Anemia of chronic disease/inflammation:
 Infections
 Malignancies
 Chronic kidney disease
 Autoimmune diseases
Therapy with erythrocyte-stimulating 
agents (ESA)
Hepcidin-producing adenomas
Iron-refractory iron deficiency anemia 
(IRIDA)
Copper deficiency
Molecular defects in 
iron transport,recycling, 
and utilization





Hereditary sideroblastic anemias (ALAS 2 
mutations)
Heme oxygenase deficiency
Patients with inflammatory bowel diseases often display a combined form 
of absolute and relative iron deficiency
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Blood transfusions should be used diligently because 
of their possible risk for morbidity and even mortality 
(increased risk of infection, transfusion reactions, lung 
injury, alloimmunization, stroke, myocardial infarction, 
transmission of yet unidentified pathogens, thrombo-
embolic complications, kidney injury, and cancer recur-
rence) [25, 32–36].
ESA can reduce transfusion requirements in cancer 
patients [37]. However, only 30–75 % of patients respond 
to ESA [38–40]. In addition, ESA can lead to an increased 
rate of thromboembolic events and, if used off-label 
in patients not currently receiving chemotherapy, to 
increased mortality [41]. For these reasons, both the 
European (EMA) and US (FDA) regulatory authorities 
have strictly limited their use [42–44].
Iron therapy for functional iron deficiency is an estab-
lished treatment in nephrology but relatively new in 
cancer. Importantly, oral iron administration is the treat-
ment of choice in asymptomatic or mildly symptomatic 
patients with FID or AID and no clinical or subclinical 
inflammation [25, 45]. The latter is a typical phenom-
enon of cancer, making malignant diseases unsuitable 
for oral iron therapy. In cancer, enteral iron absorption 
is severely impaired with more than 95 % being excreted 
via feces. Furthermore, only an insufficient amount of 
resorbed iron and intracellular storage iron is available 
for the erythroblasts because of the cytokine-induced 
disturbances of iron metabolism as described above. AID 
should always be treated in cancer and FID if associated 
with symptoms and/or relevant anemia.
Available drugs for iron treatment
Table  2 shows a summary of oral and intravenous iron 
preparations (single agent preparations) available in 
Austria. Oral preparations can be composed of bivalent 
or trivalent iron, but in Austria, all available preparations 
contain bivalent iron, which is better tolerated. Intrave-
nous iron formulations contain trivalent iron bound to 
carbohydrate or dextran carriers (hydroxide-dextran, 
hydroxide-saccharose, isomaltoside, and carboxymalt-
ose). High doses of iron (approximately 1 g per infusion) 
can be administered as single dose with the newer iron 
preparations ferric carboxymaltose or Fe (III)-or ferric-
isomaltoside, thus reducing the need for more hospital 
visits.
Ferric carboxymaltose consists of a ferric hydroxide 
core encased in a carbohydrate shell and allows con-
trolled iron release to target tissues after intravenous 
injection. In a single infusion of ferric carboxymaltose 
approximately 1000  mg of iron can be administered in 
approximately 15 min without the risk of releasing larger 
amounts of free, ionized iron into the circulation. Ferric 
carboxymaltose is rapidly cleared from plasma—approx-
imately 80 % enters the bone marrow and the rest the liver 
and spleen [46]. Fe (III)-isomaltoside possesses similar 
favorable properties. In this formulation, iron is bound 
to a matrix which prevents excessive release of free iron. 
dropped significantly in the control group. A decoupling 
of ferritin and TSAT was also shown in a different group of 
patients suffering from either hematological malignan-
cies or solid tumors. In 22 % of patients with a serum fer-
ritin between 100 and 800 ng/ml and in 24 % of patients 
with a serum ferritin ≥ 800 ng/ml iron deficiency anemia 
was observed (TSAT < 20 %, Hb < 12  g/dl) [27]. Notably, 
measurements of TSAT have some limitations. In inflam-
matory diseases, the reduced expression of transferrin 
receptors in the diminished pool of erythroblasts can 
result in a falsely high transferrin saturation [28].
Many modern hematology analyzers provide infor-
mation about the iron content of red cells and of reticu-
locytes. More than 5 % of hypochromic red cells and/or 
less than 26  pg reticulocyte hemoglobin are indicative 
of iron deficiency. Both tests are cheap and informative, 
but are rarely used. Serum levels of transferrin receptors 
(sTfR) are increased in AID, but normal in FID. The fer-
ritin index (sTfR/log ferritin) provides information about 
body iron stores even in the presence of inflammation 
when ferritin levels usually are increased because ferritin 
is a member of the acute phase proteins.
Clinical consequences of iron deficiency in 
cancer patients
The most important consequence of Fe deficiency is the 
risk for developing anemia or the aggravation of already 
existing anemia. Clinical sequelae of anemia can be 
manifold with impairment of quality of life being most 
frequent [13]. This usually is accompanied by deteriora-
tion of the performance status [4], and often by inability 
to adhere to therapy or to the scheduled dose of chemo-
therapy. These complications usually are associated with 
impaired outcome.
The mere occurrence of iron deficiency may be 
associated with several complications. Typical symp-
toms are pallor, cold skin, weakness and fatigue [29], 
reduced physical fitness [30], brittle nails, angular chei-
losis, impairment of cognitive functions [31], headaches, 
insomnia, restless legs syndrome, depression, loss of 
libido, dyspnea, tachycardia, thrombocytosis, increased 
thromboembolic complications, alopecia, and in rare 
severe cases Plummer–Vinson syndrome.
Therapeutic options and goals
The goals of anemia therapy are the avoidance of red 
blood cell transfusions and the improvement in qual-
ity of life. The aims of therapy of iron deficiency are the 
improvement or avoidance of anemia and the normaliza-
tion of symptoms due to iron deficiency. For treatment 
of anemia in cancer patients three principal options 
are available, namely red blood cell transfusions (RBC), 
erythropoiesis-stimulating agents (ESA), and iron. The 
latter two treatments can be combined to enhance the 
effectiveness of either one.
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management of iron deficiency have been made in the 
context of guidelines for the management of cancer or 
chemotherapy-induced anemia by the “National Com-
prehensive Cancer Network” (NCCN) or in guidelines 
on the use of ESA by ASH (American Society of Hema-
tology)/ASCO (American Society of Clinical Oncol-
ogy), EORTC (European Organisation for Research and 
Treatment of Cancer), and ESMO (European Socierty of 
It can also be administered in doses of up to 1000 mg of 
iron within a short infusion time.
Recommendations of current guidelines
Up to now international scientific organizations have 
not issued specific guidelines for iron supplementa-
tion in cancer patients. Only a few comments regarding 
Table 2 Iron preparations (monopreparations) licensed in Austria. (Source: Austrian prescribing information (online, as of 
September 2013); for detailed information on application and contraindications, refer to the respective prescribing information)
1. Oral preparations
Galenic Iron content (mg) Registered trade name
Iron (Fe)(II)-Fumarate Capsules 100 Ferretab®
Fe(II)-Gluconate Effervescent tablets 100 Loesferron® forte
Fe(II)-Sulfate Coated tablets 105 Ferrogradumet®
Fe(II)-Sulfate Sustained-release tablets 80 Tardyferon®
2. Intravenous preparations
Iron-compound Iron content (mg/ml) Registered trade name Age restriction Maximum single dose
2.1 Dextran-based preparations
Fe(III)-isomaltosidea 100 Monofer® Not recommended under 18 
years of age
1000 mg (20 mg/kg body 
weight)
Fe(III)-hydroxide dextranec 50 Cosmofer® Not recommended under 14 
years of age
20 mg/kg body weight
2.2 Non-dextran-based preparations
Fe(III)-carboxymaltosec 50 Ferinject® 14 years and above 1000 mg (20 mg/kg body 
weight)
Fe(III)-hydroxide-saccharosec 20 Fermed® Not recommended in children 200 mg
Fe(III)-hydroxide-saccharosec 20 Venofer®
Fe(III)-hydroxide-saccharosec 20 Ferrologic®
aIndication: iron deficiency anemia;
bIndication: iron deficiency anemia in chronic kidney disease;
cIndication: iron deficiency
Table 3 Recommendations of international societies on therapy of anemia and iron deficiency in cancer patients and national 
(Austrian) recommendations for the application of intravenous iron preparations
Society Recommendations
NCCN [45] Monotherapy with intravenous Fe in AID (ferritin < 30 ng/ml, TSAT < 20 %) indicated; no studies on iron monotherapy in FID; in 
patients with ferritin between 30 and 100 ng/ml and TSAT between 20 und 50 %, adequate storage iron can be assumed with 
the exception of patient receiving ESA which are at risk for FID. In the latter situation iron supplementation is recommended, if 
the expected benefit is larger than the expected risk. Iron should not be administered to patients with active infection!
ASH/ASCO [41] Iron monitoring recommended. Iron supplementation is recommended in case of iron deficiency, but satisfactory data for detailed 
recommendations for iron therapy and monitoring are not available.
ESMO [47] Periodic monitoring of iron homeostasis; intravenous iron induces greater increases in Hb than oral iron and reduces transfusion 
need.
EORTC [48] Administration of iron should be restricted to patients with AID or FID.
Austrian Consensus Group AID (TSAT < 20 % and ferritin < 30 ng/mla)
Oral iron should preferentially be used in non-cancer patients without inflammation (CRP normal), cancer patients in complete 
remission and patients without inflammatory diseases.
B) Intravenous iron should be administered in cancer patients with AID (TSAT < 20 % and ferritin <100 µg/Lb)
A) Intravenous iron should be considered in cancer patients symptomatic due to FID
B) Intravenous iron and ESAs should be considered in patients with chemotherapy-induced anemia and planned or ongoing ESA 
therapy
NCCN National Comprehensive Cancer Network, AID absolute iron deficiency, FID functional iron deficiency
See above: a in cancer patients < 100 ng/ml, b ≥ 100 ng/ml
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compared to treatment with ESAs only. In one trial [54] 
a numerical, but statistically non-significant increase in 
response rate was noted with intravenous iron/ESA com-
pared to ESA alone [25]. A post hoc analysis of this study 
showed much lower response rates in patients with high 
compared to those with low hepcidin levels [55]. Another 
study showed that the combination of intravenous iron 
and ESAs might also be more cost effective compared to 
ESAs alone [56].The increase in response rates by addi-
tion of intravenous iron to ESAs depends on the iron sta-
tus of the included patient cohort. Intravenous iron led to 
a further increment in response rates of 13–19 % [50–53] 
when patients without FID were treated; but response 
rates increased by 34–43 % when patients with FID were 
included [26, 49]. A meta-analysis of eleven studies 
including 1681 cancer patients randomizing patients to 
treatment with an intravenous iron preparation (from 
different sources) confirmed the activity of intravenous 
iron either as sole treatment or in combination with ESAs, 
which were used in 9 out of the 11 trials [57]. With the 
addition of intravenous iron to ESAs as backbone therapy 
a significant increase in the hematological response rates 
was noted in seven trials (relative risk [RR] 1.28). Also a 
significant reduction of transfusion needs was noted (RR 
0.76 with ESA and 0.52 without ESA). The increase in the 
hematological response rates correlated with the total 
dose of intravenous iron and was independent of base-
line iron status. Mortality and tolerability did not differ 
between patients with and without intravenous iron.
Another meta-analysis [58] showed similar results: 
hematological response rates increased by 29 % with the 
addition of intravenous iron to ESA therapy while treat-
ment with oral iron was not effective. A similar pattern 
was noted for transfusion requirements. Intravenous 
iron reduced transfusion need by 23 % but oral iron was 
ineffective. Use of intravenous iron shortened the time to 
hematological response by one month without increas-
ing toxicity.
Intravenous iron as monotherapy
Studies on the efficacy of intravenous iron as sole treat-
ment for cancer-associated anemia or chemotherapy-
induced anemia are scarce. Three small trials showed 
a significant reduction of transfusion requirements by 
intravenous administration of  iron sucrose in patients 
with gynecological tumors, receiving chemoradiother-
apy or platinum-based chemotherapy (40–64 %, p = 0.04 
[59], 22.7–63.6 %, p < 0.01 [60], and 28.1–56.3 % [61]). In 
25 non-iron-deficient anemic patients with a baseline-
Hb value of 9.6 g/dl, weekly application of 200 mg  iron 
sucrose through a maximum of 12 weeks led to an 
increase of Hb concentration by 1.6–2.1 g/dl in patients 
who had received at least 9 of 12 doses. Five patients 
were assessed as non-responders to intravenous iron 
and received blood transfusions [62]. Recently, an obser-
vational study with ferric carboxymaltose (FCM) was 
conducted in 68 hematological–oncological practices in 
Germany. A total of 639 cancer patients were included, 
Medical Oncology). These are summarized in Table 3 and 
presented in some detail below.
According to the NCCN guidelines on cancer- and 
chemotherapy- induced anemia [45], oral or intravenous 
iron monotherapy should be considered in absolute iron 
deficiency, defined as ferritin < 30 ng/ml and TSAT < 20 %. 
In patients with a ferritin level between 30 and 100 ng/
ml and a TSAT between 20 and 50 %, iron stores can be 
considered sufficient if these patients do not receive ESA. 
If such patients receive ESA, those who respond to that 
treatment run the risk of developing FID. Such patients 
likely benefit from treatment with intravenous iron.
In anemic patients with a TSAT < 20 % a combination 
of intravenous iron and ESA should be used. In patients 
with a TSAT between 20 and 50 %, the application of 
intravenous iron on top of ESA should only be considered 
if the expected benefit clearly outweighs the risks associ-
ated with this treatment. Patients with active infections 
should not receive intravenous iron.
The shared “American Society of Hematology/Ameri-
can Society of Clinical Oncology clinical practice guideline 
on the use of epoetin and darbepoetin in adult patients 
with cancer” (update 2010) [41] demands monitoring of 
iron homeostasis at the beginning and during the course 
of ESA therapy; if needed, iron supplementation should 
be given in order to improve the efficacy of ESAs, reduce 
the necessary ESA doses and the patient’s symptoms. 
However, there are insufficient data to recommend opti-
mal timing and the best intervals for iron monitoring.
The guidelines of the “European Society for Medical 
Oncology” (ESMO) [47], also from 2010, recommend 
periodic monitoring of iron homeostasis (iron, CRP, 
transferrin, and ferritin) as well. Furthermore, they state 
that intravenous administration of iron in patients with 
iron deficiency leads to larger Hb increase than oral or 
no iron supplementation, and that iron supplementation 
also seems to reduce the number of patients receiving 
blood transfusions.
Finally, the reappraisal of the ESMO and EORTC 
guidelines for the management of anemia and iron defi-
ciency in patients with cancer-related or chemotherapy-
associated anemia include now clear recommendations 
for the use of intravenous iron in  these patients [48]. 
Intravenous iron should be considered in patients with 
Hb ≤ 11 g/dl, or Hb decrease by ≥ 2 g/dl and AID or FID 
even as sole treatment. If an ESA is considered this should 
be done before initiation of ESA therapy.
Current evidence
Intravenous iron in combination with ESA
There are currently seven fully published trials compar-
ing the combination of intravenous iron and ESAs with 
ESAs alone. Six [26, 49–53] show significantly higher 
hematological response rates, shorter time to response, 
higher quality of life if measured, reduction in transfusion 
need, and lower ESA usage with the combined therapy as 
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Recommendations for clinical practice
In the following paragraph, the level of evidence and 
the grade of recommendation is assessed according to 
an algorithm established by the Oxford Institute of Evi-
dence-Based Medicine [69], which is included in the 
appendix to this publication.
1. Diagnosis of iron deficiency and indication for iron 
supplementation
 – Which parameters of iron metabolism should be 
measured?
Ferritin and TSAT should be routinely measured; option-
ally the following parameters should be determined: 
percentage of hypochromic red cells (%HYPO), Hb con-
tent of reticulocytes (CHr), soluble transferrin receptor 
(sTfR), and the ferritin index (sTfR/log ferritin).
Level of Evidence 3, Grade of Recommendation C
 – What is the indication for initiation of intravenous 
iron therapy?
Intravenous iron therapy should be started in patients 
with AID independent of the actual Hb level. This is par-
ticularly important in cancer patients scheduled for sur-
gery, where iron deficiency should be corrected whenever 
possible before the planned intervention. FID should be 
corrected by intravenous iron if patients are symptomatic 
because of iron deficiency and/or of anemia and in those 
being scheduled for ESA therapy. In patients with high 
ferritin levels (> 500 ng/ml) iron supplementation should 
be based on individual decisions [70]. Intravenous iron 
supplementation should be withheld in those with fer-
ritin levels > 1000 ng/ml [72].
Level of Evidence 2b, Grade of Recommendation B
 – How does age and comorbidity impact the decision 
for treating iron deficiency and/or anemia?
Higher age and coexistent comorbidities increase the risk 
for symptoms due to AID, FID, and anemia: Iron defi-
ciency should be corrected in all patients symptomatic 
because of ID. As increasing age and comorbidities do 
increase the risk for clinical sequelae, treatment should 
be initiated without delay.
Level of Evidence 2b, Grade of Recommendation B
2. Is there an indication for treating every patient with 
FID?
If iron deficiency and anemia do not impair the patient’s 
quality of life or do not cause any untoward symptoms 
therapy of FID can be withheld, but the patient should be 
out of which 619 received at least one dose of FCM [63]. 
Mean Hb levels increased by 1.4 g/dl (n = 233) with FCM 
alone and by 1.6 g/dl (n = 46) with FCM plus ESAs. Similar 
improvements in Hb were seen with FCM in patients with 
both baseline Hb of ≤ 11 g/dl and serum ferritin ≤ 500 ng/
ml and in those with serum ferritin above 500 ng/ml and 
low transferrin saturation (TSAT < 20 %). Patients with 
ferritin levels < 500 ng/ml showed a tendency for higher 
increases in Hb compared to those with higher baseline 
serum ferritin concentration. FCM was well tolerated. 
The rate of therapy-related adverse events was 2.3 %. 
Further studies on the effects of intravenous iron prepa-
rations in oncological patients are currently ongoing. 
Recently, a small prospective randomized trial was pub-
lished which compared a single dose of intravenous iron 
(FCM 1000  mg) with no treatment (controls) in anemic 
patients (Hb 8.5–10.5 g/dl, TSAT < 20 %, Ferritin > 40 ng/
ml in men and > 30  ng/ml in women) with low grade 
non-Hodgkin lymphomas and previous chemotherapy. 
The rise of the median Hb level was significantly higher 
in the group with intravenous iron therapy than in the 
control group (Hb 2.5 vs. 0.9 g/dl, p < 0.05) [64].
Tolerability and adverse effects of intravenous iron
Iron is an important growth factor for rapidly proliferating 
cells including bacteria or tumor cells [19, 65]. Hence, it 
is important to review the safety of intravenous high dose 
iron supplementation. Currently there is no evidence 
that intravenous iron may increase the risk for infections 
or tumor growth in cancer patients, but this issue has not 
carefully been studied as yet. An in vitro study with breast 
cancer cell lines reported that intracellular iron depletion 
by inhibiting transferrin receptor expression with siRNA 
resulted in increased expression of VEGF and increased 
angiogenesis thereby creating a favorable environment 
for tumor proliferation [66]. Intravenous iron supple-
mentation of patients with non-Hodgkin lymphomas 
had no negative impact on progression-free survival after 
more than 3 years follow-up [67]. Likewise, no increased 
risk for cardiovascular complications, tumor incidence, 
and tumor progression was reported.
In the large observational study with ferric carboxy-
maltose as sole treatment or in combination with ESAs 
therapy-related side effects were noted in only 2.3 % of 
patients. The most frequent complications were nausea 
and diarrhea. In all, 97 % of the physicians participating 
in this survey rated the efficacy and tolerability of FCM as 
“very good” or “good” [63].
In 665 patients with terminal kidney failure and 
chronic hemodialysis, treated with intravenous  iron 
sucrose, no increased rate of infections was found; on 
the contrary, this group showed a significantly lower risk 
for hospitalization caused by infections (p < 0.001) and—
although not significantly—a lower risk of mortality 
(p = 0.08) compared to the general hemodialysis popula-
tion [68]. Currently, active infections and intolerance are 
the main contraindications and limitations of intrave-
nous iron supplementation [3, 25].
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Level of Evidence 1a, Grade of Recommendation A
 – Which intravenous iron preparation should be used?
Although newer iron dextran preparations are much safer 
than the previously used intramuscular iron dextran for-
mulations they tend to show a higher risk profile than 
the other modern preparations. The newer preparations, 
like iron carboxymaltose or iron isomaltoside bind iron 
tightly to their carbohydrate shell resulting in much less 
release of free iron and potentially toxic free oxygen spe-
cies. This allows the administration of high doses within 
one infusion enhancing patient comfort and reducing 
multiple visits in the clinic.
Recent EMA recommendations do no longer require 
the application of a test dose of intravenous iron, but 
require administration of intravenous iron only in insti-
tutions, which have adequate emergency procedures in 
place. Allergic reactions can occur at first administration 
but also in patients who tolerated the same preparation 
previously. Care should also be taken that iron will be 
administered strictly intravenously, since paravenous 
extravasation of iron preparations may induce severe tis-
sue necrosis.
Level of Evidence 3, Grade of Recommendation C
3. What are the target values of iron therapy?
TSAT should rise above 20 %, ferritin clearly above 30 ng/
ml. Further target parameters are: reduction of the per-
centage of hypochromic erythrocytes (%HYPO) to < 5 %, 
increase in Hb of reticulocytes (CHr) to > 28 pg, normal-
ization of levels of soluble transferrin receptor (levels 
vary depending on the local laboratory), and normaliza-
tion of the ferritin index (sTfR/log ferritin).
Level of Evidence 3, Grade of Recommendation C
4. What is the optimal duration and dose of intrave-
nous iron therapy?
Usually a loading dose with 1000 mg of intravenous iron 
will result in adequate iron supply. If lower doses such 
as 200 mg per infusion are used, repeated administration 
in weekly or two-weekly intervals is recommended to 
increase TSAT > 20 %. Ferritin levels will increase as well, 
but treatment should be discontinued if ferritin increases 
above 800 ng/ml. Long-term treatment with intravenous 
iron should be avoided in patients with cancer as safety 
data for prolonged use in cancer are not available as 
yet. There is practical experience with this approach in 
nephrology where patients frequently receive iron sup-
plementation over several years. So far, in these popula-
tions neither an increased infection rate nor an increase 
in tumor incidence were found [68, 72].
monitored carefully in order to start therapy if symptoms 
or anemia occur.
Level of Evidence 2b, Grade of Recommendation B
 – What is the indication for red blood cell transfusions?
Patients with life threatening anemia or with severe 
symptoms due to anemia should immediately be treated 
with RBC transfusions. The trigger Hb level is higher 
in elderly patients (Hb 8/dl) and between 6–8  g/dl in 
younger fit patients. Initially, only one unit of RBC should 
be administered. In case of insufficient improvement a 
second or rarely a third unit should be given.
In the absence of an urgent need for a rapid increase 
of Hb levels alternatives to RBC transfusions like ESAs 
(in chemotherapy-associated anemia) and/or supple-
mentation of iron deficiency (in case of ID) should be 
considered.
Level of Evidence 2a, Grade of Recommendation B
 – What is the indication for erythropoiesis-stimulating 
agents (ESAs)?
Treatment with ESAs should be considered in patients 
with symptomatic chemotherapy-induced anemia and 
Hb levels < 10  g/dl. ESA should only be given during 
ongoing chemotherapy until 4 weeks after discontinu-
ation of chemotherapy. The only exception to this rec-
ommendation are patients with low and intermediate 
risk MDS. Those without cytogenetic abnormalities and 
endogenous erythropoietin levels < 500  ng/ml are more 
likely to respond, but response may take longer than in 
other cancers. The target Hb level is 10–12 g/dl.
Level of Evidence 1c, Grade of Recommendation A
 – What is the indication for intravenous iron as mono-
therapy?
Oral iron is a valuable option for non-cancer patients with 
AID without inflammation, with few symptoms only, and 
without an urgent need for anemia correction. Similar 
recommendations apply to cancer patients in complete 
or very good remission with AID. In patients with active 
cancer who are symptomatic due to FID, treatment with 
intravenous iron should be considered.
Level of Evidence 2b, Grade of Recommendation B
 – What is the indication for intravenous iron in combi-
nation with ESA?
In patients who are symptomatic due to anemia and/or 
iron deficiency fulfilling the criteria for iron deficiency 
(TSAT < 20 % and ferritin < 500 ng/ml) and scheduled for 
ESA therapy, concomitant treatment with intravenous 
iron should be considered.
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Fig. 1 Diagram of iron resorption and metabolism (with kind permission of Evstatiev R, Gasche Ch, and “Gut”)
 
Fig. 2 Hepcidin—central regulator of iron uptake and release (with kind permission of Evstatiev R, Gasche Ch, and “Gut”)
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Level of Evidence 4, Grade of Recommendation C
5. Which follow-up examinations are recommended?
Pharmacoepidemiological studies indicate that iron 
status in cancer patients frequently is not assessed [71]. 
Parameters that should be evaluated are those of iron 
metabolism as mentioned above, hemoglobin and red 
cell parameters. The outcome of intravenous iron sup-
plementation should  be controlled only after 2–4 weeks 
of iron administration (Figs. 1, 2).
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